2020年10月13日

Kanaph疗法关闭21 m美元系列B资金首尔,韩国,10月12日2020 / Kanaph疗法,从领先的生物技术在肿瘤、自身免疫性疾病、眼病和大分子和小分子,最近完成了系列B资助21 m美元在韩国。在这一轮中,韩国大型制药公司,GC制药,Kolon等和风险资本基金投资,Timefolio资产管理和更多的参与融资。除了2 m美元的天使资金和6 m系列美元资金,Kanaph筹集总计30美元。Kanaph面前跑步者是bi-specifics immuno-oncology TMEkineTM平台,和bi-specific Fc-fusion抑制替代补充和血管生成途径治疗视网膜疾病。他们的小分子管道包括开发新型小分子针对特定突变信号通路或删除immune-suppressive环境由肿瘤。Kanaph集中在3个小分子计划在这方面:第四代表皮生长因子受体抑制剂针对C797S,双重EP2/4抑制剂和喀斯特通路中的目标不明,在前两个是在2021年初进入临床阶段。TMEkineTM,抗体平台,是建立在技术许可从美国顶尖大学和集成到一个antibody-cytokine双特异性平台,可以克服现有immuno-oncology疗法的最大的未满足的需求或没有响应病人治疗组。TMEkineTM分子符合最近immuno-oncology领域的趋势,已转换的肿瘤免疫疗法不回应,也称为冷肿瘤,肿瘤成热。该平台还可以扩展到多种不同的适应症。管理团队在Kanaph广泛研究和药物开发等公司基因泰克和安进的经验。 The CEO of Kanaph, Byoung Chul Lee has a strong track record in antibody drug discovery and development stemming from his experience in Genentech, 23andMe and Santen. This round of funding will go towards expediting the clinical development of Kanaph's pipelines. Candidates eligible are TMEkineTM molecules for immuno-oncology and bi-specific Fc fusions for the treatment of retinal diseases. A CDO agreement was recently signed with Samsung Biologics for the development of KNP-301 (retinal disease therapy) for the clinic. The funds will provide a basis for completing preclinical studies for a number of pipelines at the end of this year or the beginning of next year and they will be licensed out once their preclinical packages are ready for the next steps. View original content: http://www.prnewswire.com/news-releases/kanaph-therapeutics-closes-21m-usd-series-b-funding-301150692.html